These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 34751766)

  • 1. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
    Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
    Wlazlo M; Meglicka M; Wiernicka A; Osiecki M; Matuszczyk M; Kierkus J
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):54-61. PubMed ID: 38477410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
    Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.
    Dulai PS; Wong ECL; Reinisch W; Colombel JF; Marshall JK; Narula N
    Inflamm Bowel Dis; 2022 Oct; 28(10):1555-1564. PubMed ID: 34967397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
    Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
    BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
    J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
    Mocci G; Tursi A; Maconi G; Cataletti G; Mantia B; Serio M; Scarcelli A; Pagnini C; Graziani MG; Di Paolo MC; Pranzo G; Luppino I; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Ferronato A; Perini B; Savarino E; Onidi FM; Binaghi L; Usai Satta P; Schiavoni E; Napolitano D; Scaldaferri F; Pugliese D; Pica R; Cocco A; Zippi M; Rodino S; Sebkova L; Rocco G; Sacchi C; Zampaletta C; Gaiani F; De Angelis G; Kayali S; Fanigliulo L; Lorenzetti R; Allegretta L; Scorza S; Cuomo A; Donnarumma L; Della Valle N; Sacco R; Forti G; Antonelli E; Bassotti G; Iannelli C; Luzza F; Aragona G; Perazzo P; Lauria A; Piergallini S; Colucci R; Bianco MA; Meucci C; Giorgetti G; Clemente V; Fiorella S; Penna A; De Medici A; Picchio M; Papa A
    Expert Opin Biol Ther; 2023 Mar; 23(3):293-304. PubMed ID: 36843568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
    Allegretti JR; Barnes EL; Stevens B; Storm M; Ananthakrishnan A; Yajnik V; Korzenik J
    Dig Dis Sci; 2017 Jun; 62(6):1590-1596. PubMed ID: 28357697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
    Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
    Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
    United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
    Dig Dis Sci; 2023 Jun; 68(6):2658-2666. PubMed ID: 36645636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
    Sablich R; Urbano MT; Scarpa M; Scognamiglio F; Paviotti A; Savarino E
    Sci Rep; 2023 Feb; 13(1):1816. PubMed ID: 36725872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
    Jossen J; Kiernan BD; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):304-309. PubMed ID: 31738290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
    J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.